| Olaparib studied in …STUDIED_INderived200 of 351show all (up to 200) |
|---|
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 351 trials list this drug (156 active) | — | — | Ovarian Endometrioid Tumor,Ovarian Serous Tumor,Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03842228Phase 1 · active not recruiting Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · 351 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03976323Phase 3 · completed Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) · 351 trials list this drug (156 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04086485Phase 1/Phase 2 · recruiting Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) · 351 trials list this drug (156 active) | — | — | Neuroendocrine Neoplasm,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,Malignant Solid Neoplasm,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03568656Phase 1/Phase 2 · completed Study to Evaluate CCS1477 in Advanced Tumours · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03741426Phase 2 · recruiting WIRE - Novel Treatments in Renal Cell Cancer · 351 trials list this drug (156 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858334Phase 2 · recruiting APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · 351 trials list this drug (156 active) | — | — | Pancreatic Carcinoma,Pancreatic Squamous Cell Carcinoma,Pancreatic Acinar Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966700Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04417062Phase 2 · active not recruiting Olaparib With Ceralasertib in Recurrent Osteosarcoma · 351 trials list this drug (156 active) | — | — | Osteosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624204Phase 3 · active not recruiting Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) · 351 trials list this drug (156 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02484404Phase 1/Phase 2 · active not recruiting Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02693535Phase 2 · recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04538378Phase 2 · terminated Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03486873Phase 3 · recruiting Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) · 351 trials list this drug (156 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04038502Phase 2 · recruiting Carboplatin or Olaparib for BRcA Deficient Prostate Cancer · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353386Phase 1/Phase 2 · recruiting Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) · 351 trials list this drug (156 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974621Phase 2 · active not recruiting Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma · 351 trials list this drug (156 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524935Phase 2 · active not recruiting Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · 351 trials list this drug (156 active) | — | — | Ocular Melanoma,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05898399Phase 1/Phase 2 · recruiting Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06177171Phase 1 · active not recruiting Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06915025Phase 3 · recruiting Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer · 351 trials list this drug (156 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090567Phase 2 · recruiting Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191135Phase 2 · terminated Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) · 351 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03775486Phase 2 · active not recruiting Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04633239Phase 1 · recruiting Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Platinum-Resistant Ovarian Carcinoma,Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03953898Phase 2 · active not recruiting Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation · 351 trials list this drug (156 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04394858Phase 2 · active not recruiting Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer · 351 trials list this drug (156 active) | — | — | Paraganglioma,Adrenal Gland Pheochromocytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06797635Phase 2 · recruiting Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652242Phase 1 · recruiting Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03212274Phase 2 · active not recruiting Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm,Glioblastoma,Glioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03317392Phase 1/Phase 2 · active not recruiting Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis · 351 trials list this drug (156 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585958Phase 1 · recruiting Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm,Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208375Phase 1 · active not recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian · 351 trials list this drug (156 active) | — | — | Breast Carcinoma,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04005690early Phase 1 · recruiting Targeted Pathway Inhibition in Patients With Pancreatic Cancer · 351 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06298084Phase 1/Phase 2 · recruiting Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06245889Phase 2 · recruiting PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC · 351 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06909825Phase 2 · active not recruiting FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06488378Phase 1 · recruiting Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,PALB2 Hereditary Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209686Phase 2 · completed Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma · 351 trials list this drug (156 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02849496Phase 2 · active not recruiting Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · 351 trials list this drug (156 active) | — | — | Carcinosarcoma,Endometrioid Adenocarcinoma,Endometrial Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171816Phase 3 · active not recruiting Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · 351 trials list this drug (156 active) | — | — | Fallopian Tube Endometrioid Tumor,Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05463848Phase 2 · active not recruiting Surgical Pembro +/- Olaparib w TMZ for rGBM · 351 trials list this drug (156 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740165Phase 3 · completed Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) · 351 trials list this drug (156 active) | — | — | Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03732820Phase 3 · active not recruiting Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742895Phase 2 · active not recruiting Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05286827Phase 2 · terminated Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma · 351 trials list this drug (156 active) | — | — | Pancreatic Acinar Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02769962Phase 1/Phase 2 · terminated Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer · 351 trials list this drug (156 active) | — | — | Lung Neoplasm,Urothelial Carcinoma,Lung Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03943173early Phase 1 · active not recruiting Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery · 351 trials list this drug (156 active) | — | — | BRCA Hereditary Ovarian Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07382544Phase 1 · recruiting Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · 351 trials list this drug (156 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03851614Phase 2 · active not recruiting Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Leiomyosarcoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04269200Phase 3 · active not recruiting Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer · 351 trials list this drug (156 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma,Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00777582Phase 1 · active not recruiting Phase I Comparative Bioavailability Study · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01081951Phase 2 · active not recruiting Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03459846Phase 2 · active not recruiting A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) · 351 trials list this drug (156 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03085147Phase 1/Phase 2 · active not recruiting A Dye for the Detection of Cancer of the Tongue and Mouth · 351 trials list this drug (156 active) | — | — | Oral Cavity Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · 351 trials list this drug (156 active) | — | — | Low Grade Fallopian Tube Serous Adenocarcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Seromucinous Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554328Phase 2 · active not recruiting Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial · 351 trials list this drug (156 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Endometrial Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878095Phase 2 · active not recruiting Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02893917Phase 2 · active not recruiting Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer · 351 trials list this drug (156 active) | — | — | Prostate Adenocarcinoma,Prostate Adenocarcinoma with Neuroendocrine Differentiation,Prostate Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03259503Phase 1 · completed Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant · 351 trials list this drug (156 active) | — | — | Hodgkin Lymphoma,T-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01874353Phase 3 · active not recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02029001Phase 2 · recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 351 trials list this drug (156 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04053322Phase 2 · active not recruiting Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06856499Phase 1 · recruiting Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06545942Phase 1 · recruiting Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07641855Phase 2/Phase 3 · not yet recruiting A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238922Phase 1 · active not recruiting Study of INCB123667 in Subjects With Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03579316Phase 2 · active not recruiting Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 351 trials list this drug (156 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116648Phase 1/Phase 2 · active not recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Fallopian Tube Carcinoma,Ovarian Endometrioid Adenocarcinoma,Ovarian Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02032823Phase 3 · active not recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02734004Phase 1/Phase 2 · active not recruiting A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. · 351 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05568550Phase 2 · recruiting Pembro With Radiation With or Without Olaparib · 351 trials list this drug (156 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02861573Phase 1/Phase 2 · active not recruiting Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04748042Phase 2 · active not recruiting Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) · 351 trials list this drug (156 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05887609Phase 2 · recruiting An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib · 351 trials list this drug (156 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06112379Phase 3 · active not recruiting A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02813135Phase 1/Phase 2 · recruiting European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors · 351 trials list this drug (156 active) | — | — | Childhood Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04711824Phase 1/Phase 2 · active not recruiting Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05411094Phase 1 · active not recruiting Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer · 351 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498272Phase 2 · active not recruiting Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations · 351 trials list this drug (156 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737643Phase 3 · active not recruiting Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121401Phase 4 · active not recruiting First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients · 351 trials list this drug (156 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02489006Phase 2 · active not recruiting A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · 351 trials list this drug (156 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03991832Phase 2 · active not recruiting Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Glioma,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123366Phase 2 · completed Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03263650Phase 2 · completed Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC · 351 trials list this drug (156 active) | — | — | Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04197713Phase 1 · active not recruiting Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05093231Phase 2 · recruiting Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · 351 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04421963Phase 3 · active not recruiting Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375307Phase 2 · active not recruiting Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes · 351 trials list this drug (156 active) | — | — | Genitourinary System Carcinoma,Malignant Bladder Neoplasm,Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04728230Phase 1/Phase 2 · active not recruiting Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial · 351 trials list this drug (156 active) | — | — | Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05379972Phase 2 · completed Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers · 351 trials list this drug (156 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04729387Phase 3 · terminated Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04753879Phase 2 · active not recruiting Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. · 351 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024784Phase 2 · recruiting A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies · 351 trials list this drug (156 active) | — | — | Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Female Reproductive System Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03012321Phase 2 · active not recruiting Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects · 351 trials list this drug (156 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05203445Phase 2 · active not recruiting A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02755844Phase 1/Phase 2 · completed Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients · 351 trials list this drug (156 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02308072Phase 1 · completed Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer · 351 trials list this drug (156 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042831Phase 2 · active not recruiting Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations · 351 trials list this drug (156 active) | — | — | Cholangiocarcinoma,Bile Duct Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04380636Phase 3 · active not recruiting Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) · 351 trials list this drug (156 active) | — | — | Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05255653Phase 2/Phase 3 · recruiting Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features · 351 trials list this drug (156 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04614909early Phase 1 · completed Study of Pamiparib in Newly Diagnosed and rGBM · 351 trials list this drug (156 active) | — | — | Glioblastoma,Adult Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03047135Phase 2 · active not recruiting Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441747Phase 2 · recruiting Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) · 351 trials list this drug (156 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06217757Phase 1/Phase 2 · recruiting Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC · 351 trials list this drug (156 active) | — | — | Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05933265Phase 1/Phase 2 · active not recruiting Study of LP-184 in Patients With Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Glioblastoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05156268Phase 2 · completed A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma · 351 trials list this drug (156 active) | — | — | Uterine Corpus Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03682289Phase 2 · active not recruiting Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Urothelial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05457257Phase 4 · active not recruiting Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03162627Phase 1 · active not recruiting Selumetinib and Olaparib in Solid Tumors · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06130254Phase 1 · terminated Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02679963Phase 2 · terminated Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer · 351 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03786796Phase 2 · recruiting Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations · 351 trials list this drug (156 active) | — | — | Kidney Neoplasm,Malignant Kidney Neoplasm,Kidney Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03297606Phase 2 · recruiting Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) · 351 trials list this drug (156 active) | — | — | Solid Neoplasm,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03787680Phase 2 · active not recruiting Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) · 351 trials list this drug (156 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742245Phase 1 · active not recruiting Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05340413Phase 2 · completed Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460180Phase 1/Phase 2 · recruiting The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04884360Phase 3 · active not recruiting D9319C00001- 1L OC Mono Global RCT · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02787642Phase 1 · completed A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma · 351 trials list this drug (156 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03801369Phase 2 · terminated AMTEC IIT: Phase 2 Multiarm Study in TNBC · 351 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03976362Phase 3 · completed A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) · 351 trials list this drug (156 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641755Phase 1 · active not recruiting Olaparib + Sapacitabine in BRCA Mutant Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04065269Phase 2 · active not recruiting ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06829199Phase 2 · withdrawn A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04683679Phase 2 · recruiting A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02000622Phase 3 · completed Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. · 351 trials list this drug (156 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407452Phase 2 · not yet recruiting Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03025035Phase 2 · completed Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03008278Phase 1/Phase 2 · completed Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery · 351 trials list this drug (156 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,Esophageal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05366166Phase 2 · active not recruiting Pembrolizumab Plus Olaparib in LA-HNSCC · 351 trials list this drug (156 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06712472Phase 3 · recruiting Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer · 351 trials list this drug (156 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06560632Phase 1 · terminated Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03685331Phase 1 · completed HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03344965Phase 2 · active not recruiting Olaparib In Metastatic Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02546661Phase 1 · active not recruiting Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03955640Phase 1 · terminated Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01858168Phase 1 · completed Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma · 351 trials list this drug (156 active) | — | — | Ewing Sarcoma,Rhabdomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550104Phase 1 · recruiting A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC · 351 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05240898Phase 1 · completed A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05128734Phase 2 · not yet recruiting Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · 351 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05522491Phase 2 · not yet recruiting Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01844986Phase 3 · active not recruiting Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03212742Phase 1/Phase 2 · active not recruiting Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients · 351 trials list this drug (156 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05568212Phase 2 · recruiting Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06201234Phase 2 · recruiting Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03109080Phase 1 · completed Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) · 351 trials list this drug (156 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900895Phase 1 · recruiting Estradiol Plus Olaparib for Breast Cancer (PHOEBE) · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 351 trials list this drug (156 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252390Phase 1 · terminated NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03334617Phase 2 · active not recruiting Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy · 351 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04643379Phase 2 · active not recruiting Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma · 351 trials list this drug (156 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644289Phase 2 · recruiting WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC · 351 trials list this drug (156 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03516812Phase 2 · completed Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer · 351 trials list this drug (156 active) | — | — | Prostate Adenocarcinoma,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04532645completed Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK · 351 trials list this drug (156 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03561870Phase 2 · completed Olaparib in Recurrent IDH-mutant Glioma · 351 trials list this drug (156 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05932862Phase 1 · recruiting A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04076579Phase 2 · completed Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma · 351 trials list this drug (156 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01078662Phase 2 · completed Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats · 351 trials list this drug (156 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740893Phase 2 · recruiting PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04336943Phase 2 · terminated Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load · 351 trials list this drug (156 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07090369Phase 1 · not yet recruiting Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer · 351 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069335Phase 1 · recruiting A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03534453Phase 3 · completed Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05320757early Phase 1 · completed Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients · 351 trials list this drug (156 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05870423Phase 1 · recruiting Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors · 351 trials list this drug (156 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02419495Phase 1 · terminated Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies · 351 trials list this drug (156 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05405309Phase 1/Phase 2 · terminated RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia · 351 trials list this drug (156 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02571725Phase 1/Phase 2 · active not recruiting PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06419179Phase 2 · enrolling by invitation Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) · 351 trials list this drug (156 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03834519Phase 3 · completed Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) · 351 trials list this drug (156 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03874884Phase 1 · active not recruiting 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04515836Phase 2 · recruiting Olaparib in Patients With HRD Malignant Mesothelioma · 351 trials list this drug (156 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04483544Phase 2 · terminated Pembrolizumab and Olaparib in Cervical Cancer Patients · 351 trials list this drug (156 active) | — | — | Cervical Carcinoma,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05432518early Phase 1 · recruiting Pilot Trial for Treatment of Recurrent Glioblastoma · 351 trials list this drug (156 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03594396Phase 1/Phase 2 · active not recruiting Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536128Phase 2 · recruiting Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06686030Phase 2 · recruiting Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556617Phase 1/Phase 2 · terminated PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · 351 trials list this drug (156 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04236414Phase 1 · completed Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours · 351 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05332561Phase 2 · recruiting Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) · 351 trials list this drug (156 active) | — | — | Early Stage Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05485766Phase 2 · recruiting Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer · 351 trials list this drug (156 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,BRCA Hereditary Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04330040Phase 4 · completed Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer · 351 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04306367Phase 2 · completed Study of Pembrolizumab and Olaparib in Bile Duct Cancer · 351 trials list this drug (156 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120972Phase 2 · withdrawn Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06783127recruiting Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer · 351 trials list this drug (156 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00753545Phase 2 · completed Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer · 351 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02533765Phase 2 · completed Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor · 351 trials list this drug (156 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |